Delcath Systems, Inc. (DCTH) is a medical technology company incorporated in April 1988 and based out of New York. This innovative company specializes in the design, development, and commercialization of a range of treatments for patients with advanced diseases in the liver. The focus of Delcath Systems, Inc. is to pioneer drug delivery systems that address the limitations of existing cancer treatments, particularly chemotherapy, to extend and improve the lives of patients.
The company's flagship product, CHEMOSAT® or Hepatic CHEMOSAT® Delivery System, offers a novel approach to treating cancer. It isolates the circulatory system of the liver in-order to administer high-dose chemotherapy, directly treating the liver and minimizing systemic exposure to the drug. This ground-breaking technique enables oncologists to treat liver cancers that are unresponsive to standard treatments, or are not suitable for surgical intervention. Moreover, it minimizes the negative side-effects, traditionally associated with systemic chemotherapy treatments.
Over the years, Delcath Systems, Inc. has led efforts to revolutionize patient care with its innovative drug delivery systems, transforming the lives of thousands of patients. To this end, the company engages in rigorous research, development, and clinical trials, collaborating with leading institutions and health professionals around the world.
The company's management consists of experienced professionals in the fields of medicine, biotechnology, and finance, which fosters an environment of innovation and growth. They are committed to driving the company's focus on research and development while ensuring fiscal responsibility and increasing shareholder value.
Delcath Systems, Inc. also places high emphasis on collaborative partnerships, believing that such efforts not only raise their productivity but also fuel the advancements in healthcare. They partner with a variety of entities ranging from academic hospitals, research institutes to pharmaceutical companies, with the aim to further refine their therapeutic approaches and expand their treatments’ reach.
Delcath Systems, Inc. continues to occupy a distinctive space in the oncology domain, aimed at improving patient outcomes and reducing the burden of cancer. Their advanced technological approaches have carved out their unique position in the global medical field, defining them as a forerunner in the scenario of liver disease management. As they move into the future, they are poised to continue to play a significant role in the way patients with advanced liver diseases are treated, contributing to the evolution of cancer care, and improving patients’ quality of life.